Clinical Applications

Clinuvel’s pioneering work aims at assisting those who suffer from three UV related skin disorders and two cancer related treatments. There are five clinical indications for which Clinuvel is currently testing afamelanotide (CUV1647):

• Polymorphous Light Eruption (PLE/PMLE) – likened to sun poisoning. Suffered by 10-20% of Population
• Squamous Cell Carcinoma (SCC) - non-melanoma skin cancers – and Actinic Keratosis (AK), a precursor to skin cancers, in organ transplant patients.
• Erythropoietic Protoporphyria (EPP) - absolute sun intolerance, intolerable pain suffered when exposed to light by between one in 200,000 and one in 750,000.
• Solar Urticaria (SU) – (acute) anaphylactic reaction to sun.
• Phototoxicity associated with Photodynamic Therapy (PDT) for cancer – a debilitating photosensitivity to sunlight and artificial light (skin and eyes) that can last up to 90 days after PDT treatment

More information on Clinuvel's PLE trials is available on the ClinicalTrials.gov website.
More information on Clinuvel's EPP trials is available on the ANZCTR website.

More information on all these indications can be found at Clinuvel Photoprotection.